# US 2021/0340513 A1 · Engineered enzyme

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0340513 A1
- Document ID: US20210340513A1
- Status: Published application
- Kind: A1
- Application number: 17/374,628
- Filed: 2021-07-13
- Published: 2021-11-04
- Earliest claimed: 2018-10-22
- Assignees: Inscripta, Inc.
- Applicants: Inscripta, Inc.
- Inventors: Juhan Kim; Benjamin Mijts
- Web page: https://patentgrep.com/patent/US20210340513A1

## CPC

- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/222: {Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides a novel catalytically inactive MAD7 nuclease (dMAD7) that retains the ability to bind DNA in a sequence-specific manner. The MAD7 nuclease from which the dMAD7 has been derived was isolated from Eubacterium rectale.

## Claims

### Claim 1

A catalytically inactive CRISPR nuclease derived from E. rectale MAD7 (dMAD7) having an amino acid sequence SEQ ID NO: 2.

### Claim 2 (depends on 1)

The catalytically inactive CRISPR nuclease of claim 1 for sequence-specific binding a bacteria genome.

### Claim 3 (depends on 1)

The catalytically inactive CRISPR nuclease of claim 1 for sequence-specific binding a yeast genome.

### Claim 4 (depends on 1)

The catalytically inactive CRISPR nuclease of claim 1 for sequence-specific binding an isolated mammalian cell genome.
